Clinical Trial

BPaL(M) Regimen for the Treatment of MDR/RR-TB

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The objective of this study is to analyze the efficacy of a new regimen using Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for 24 weeks or Bedaquiline, Pretomanid, Linezolid for 26 weeks for the treatment of MDR/RR-TB through the clinical trial.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-05-14; most recent amendment 2024-03-13.
Status change: Not Yet Recruiting → Recruiting 2024-03-13
Trial Details
NCT Number NCT05381194
Lead Sponsor Asan Medical Center
Collaborators: Pusan National University Hospital, Samsung Medical Center, Seoul National University Hospital, Severance Hospital, Chonnam National University Hospital, The Catholic University of Korea, Chungbuk National University Hospital, Ulsan University Hospital, Soon Chun Hyang University, Incheon St.Mary's Hospital, DongGuk University, National Medical Center, Seoul
Conditions Multidrug- and Rifampicin-resistant Tuberculosis
Enrollment 80 participants
Start Date 2022-12-13
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-03-15